MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Xenon Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

32.65 3.98

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

31.29

Max

33.4

Schlüsselkennzahlen

By Trading Economics

Einkommen

638K

-65M

Verkäufe

7.5M

7.5M

Gewinnspanne

-867.293

Angestellte

316

EBITDA

4.1M

-73M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+76.1% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-303M

2.4B

Vorheriger Eröffnungskurs

28.67

Vorheriger Schlusskurs

32.65

Nachrichtenstimmung

By Acuity

68%

32%

343 / 376 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Juli 2025, 15:46 UTC

Wichtige Markttreiber

BitMine Shares Fall After Closing of $250 Million Private Placement

9. Juli 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9. Juli 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. Juli 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9. Juli 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9. Juli 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9. Juli 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

9. Juli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juli 2025, 20:26 UTC

Ergebnisse

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9. Juli 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9. Juli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9. Juli 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9. Juli 2025, 17:07 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9. Juli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9. Juli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Health Care Roundup: Market Talk

9. Juli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Juli 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. Juli 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9. Juli 2025, 16:14 UTC

Akquisitionen, Fusionen, Übernahmen

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9. Juli 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9. Juli 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9. Juli 2025, 15:31 UTC

Wichtige Markttreiber

BitMine Shares Fall After Closing of $250M Private Placement

9. Juli 2025, 15:31 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9. Juli 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9. Juli 2025, 14:36 UTC

Akquisitionen, Fusionen, Übernahmen

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9. Juli 2025, 14:31 UTC

Akquisitionen, Fusionen, Übernahmen

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9. Juli 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9. Juli 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Peer-Vergleich

Kursveränderung

Xenon Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

76.1% Vorteil

12-Monats-Prognose

Durchschnitt 55.33 USD  76.1%

Hoch 65 USD

Tief 47 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Xenon Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

15

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

34.81 / 38.24Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

343 / 376 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.